Rheumatoid arthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 18
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• STING 0
• AKT 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Regulation of type I interferon signaling by A20 (TNFAIP3) in autoimmune and autoinflammatory disease

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$55,114 awarded in fiscal year 2026· until Oct 2029

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• NIH NIAID · F31

  Genetic and cellular mechanisms underlying resistance to gammaherpesvirus infection

  University of Vermont & St Agric College· Burlington, United States· US$34,654 awarded in fiscal year 2026· until Sept 2028

• NIH NIAMS · UG3

  Axial TReatment Agent Options; Responsiveness of Disease to Inhibition of Numerous Anti-Rheumatic pathways in Youth (AxTRAORDINARY)

  Children's Hosp of Philadelphia· Philadelphia, United States· US$453,545 awarded in fiscal year 2026· until Aug 2027

• NIH NIAMS · K08

  Transcriptional regulation of synovial tissue-resident memory CD8 T cells

  University of California, San Diego· La Jolla, United States· US$100,345 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, United Kingdom· EU contribution €4,793,228· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Sweden· EU contribution €7,995,375· until Jun 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, United Kingdom· EU contribution €150,000· until Nov 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution €2,499,750· until Apr 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €150,000· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

10 of 416 running projects, newest first. Listed amounts together: US$230.9m + €169.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

  NCT06041269· AnaptysBio, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 98
• CRISPR-Cas Systems 1
• Gene Expression Profiling 122
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 53
• Metabolomics 45
• Mass Spectrometry 8
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 59
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 162
• Genome-Wide Association Study 113

• Rare variants in genes related to inborn errors of immunity in patients with rheumatoid arthritis and secondary immunodeficiency.

  RMD Open, Jul 2026

• GATA3 Deletion Associated With Juvenile Idiopathic Arthritis: Expanding the Phenotypic Spectrum of Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia (HDR) Syndrome.

  Am J Med Genet A, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.